BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8765531)

  • 1. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
    Hay MP; Denny WA; Wilson WR
    Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
    Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
    J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
    Tercel M; Wilson WR; Anderson RF; Denny WA
    J Med Chem; 1996 Mar; 39(5):1084-94. PubMed ID: 8676343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.
    Moselen JW; Hay MP; Denny WA; Wilson WR
    Cancer Res; 1995 Feb; 55(3):574-80. PubMed ID: 7834627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
    J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
    Henderson ND; Plumb JA; Robins DJ; Workman P
    Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
    Helsby NA; Wheeler SJ; Pruijn FB; Palmer BD; Yang S; Denny WA; Wilson WR
    Chem Res Toxicol; 2003 Apr; 16(4):469-78. PubMed ID: 12703963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization.
    Sykes BM; Atwell GJ; Hogg A; Wilson WR; O'Connor CJ; Denny WA
    J Med Chem; 1999 Feb; 42(3):346-55. PubMed ID: 9986704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
    Lee HH; Wilson WR; Denny WA
    Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
    Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
    J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
    Tercel M; Lee AE; Hogg A; Anderson RF; Lee HH; Siim BG; Denny WA; Wilson WR
    J Med Chem; 2001 Oct; 44(21):3511-22. PubMed ID: 11585455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation.
    Jain M; Kwon CH
    J Med Chem; 2003 Dec; 46(25):5428-36. PubMed ID: 14640551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
    Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
    J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of DNA sequence and minor groove selective alkylating agents.
    Lee M; Rhodes AL; Wyatt MD; Forrow S; Hartley JA
    Anticancer Drug Des; 1993 Jun; 8(3):173-92. PubMed ID: 8517912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
    J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards.
    Ware DC; Palmer BD; Wilson WR; Denny WA
    J Med Chem; 1993 Jun; 36(13):1839-46. PubMed ID: 8515422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
    Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
    Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.